EPRX Announces $150M Offering to Advance EP-104GI for Eosinophilic Esophagitis, Phase 2/3 Trials, IP Expansion
Eupraxia Pharmaceuticals Inc. Common Stock · Now $6.86
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS